At a recent international academic conference, Professor Matthew Davids from the Dana-Farber Cancer Institute in the United States announced the interim analysis results of the Phase 3 randomized controlled clinical trial, BRUIN CLL-322. This study aimed to evaluate the efficacy and safety of fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR regimen) versus venetoclax plus rituximab (VR regimen) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Meletios Dimopoulos from the National and Kapodistrian University of Athens was invited to deliver a presentation titled "Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial."

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Niels van de Donk from the Amsterdam University Medical Center (Amsterdam UMC), representing the EMN30 study group, announced the updated safety run-in (SRI) results of the EMN30/MAJESTEC-4 study. This study aims to evaluate the safety and preliminary efficacy of the BCMA×CD3 bispecific antibody Teclistamab (Tec), either as monotherapy or in combination with Lenalidomide (Len), as maintenance therapy for patients with newly diagnosed multiple myeloma (NDMM) following autologous stem cell transplantation (ASCT).

At the EHA 2026 conference, Professor Omar Nadeem from the Dana-Farber Cancer Institute (USA) announced the latest results of the Phase II ImmunoPRISM trial. This study compared the BCMA×CD3 bispecific antibody Teclistamab with the standard regimen of lenalidomide + dexamethasone (Rd) in patients with high-risk smoldering multiple myeloma (HRSMM), providing heavy evidence for early precision intervention in this field.

In June 2026, the world-renowned European Hematology Association (EHA) Annual Congress grandly opened in Stockholm, Sweden. As one of the largest and most influential academic events in the global field of hematology, this year's EHA Congress not only brought together top-tier academic research results but also defined the development direction for global hematology diagnosis and treatment over the next five to ten years through the release of a series of strategic blueprints. The opening ceremony covered strategic addresses from the Board of Directors, research grant awards, DEI (Diversity, Equity, and Inclusion) and Education & Mentoring awards, as well as a highly prestigious Lifetime Achievement Award lecture. Experts showcased the rapid transformation of hematology in the era of precision medicine from a comprehensive perspective, ranging from macro-level industry policies to micro-level molecular biological mechanisms.

At the recent European Hematology Association (EHA) Annual Congress, Professor Peter Voorhees from the Atrium Health Levine Cancer Institute (Charlotte, USA) was invited to share the preliminary results of the MONUMENTAL-3 study (NCT05455320). This study is the first randomized Phase 3 clinical trial evaluating GPRC5D-targeted therapy in combination with Daratumumab ± Pomalidomide for the treatment of relapsed/refractory multiple myeloma (RRMM).

The treatment landscape for multiple myeloma (MM) has undergone revolutionary changes over the past two decades, transitioning from the traditional chemotherapy era to a golden age of precision targeting and immunotherapy. However, does immense success in clinical evidence translate to broad benefits for patients? At the 29th Annual Congress of the European Hematology Association (EHA), Professor Pieter Sonneveld, Professor of Hematology at the Erasmus University of Rotterdam Medical Center and Chairman of the European Myeloma Network (EMN), delivered a keynote speech. He not only reviewed the new benchmarks for frontline treatment represented by the PERSEUS study but also provided a forward-looking perspective on the "fragmented" reality of innovative drug accessibility across European countries. This summary aims to comprehensively present Professor Sonneveld's profound reflections on MM treatment evolution, the clinical application of MRD, and the challenges of health technology assessment.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Pratima Chowdary from the Katherine Dormandy Haemophilia and Thrombosis Centre at Royal Free Hospital, University College London (UCL), delivered an in-depth presentation titled "The future of hemophilia care: Entering an era of personalized medicine." Professor Chowdary reviewed the evolution of hemophilia care over nearly a century, focusing on the reshaping of clinical practice by extended half-life (EHL) coagulation factors, bispecific antibodies, rebalancing therapies, and gene therapy. She emphasized how to achieve precise personalized medicine through the quality framework of "Structure-Process-Outcome" amidst the current surge of innovative drugs.

At the 2026 European Hematology Association (EHA) Annual Meeting, world-renowned lymphoma expert Professor Stephen Ansell from the Mayo Clinic (Rochester, Minnesota, USA) was invited to deliver a keynote speech titled "Deciphering HL biology." Professor Ansell systematically reviewed the molecular origins of Reed-Sternberg (RS) cells in classical Hodgkin lymphoma (cHL), the abnormal activation of key signaling pathways, the complex interactions within the immune microenvironment (TME), and how these biological features drive current immunotherapy strategies while revealing future challenges in drug resistance.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Todd Knepper from Moffitt Cancer Center shared a thematic report on "Post-Transplant Molecular Surveillance Reveals Divergent Clinical Trajectories of Donor-Derived Clonal Hematopoiesis (DD-CHIP)." Through high-throughput sequencing (NGS) technology, this study explored the incidence, molecular landscape, and differentiated impact of DD-CHIP on clinical outcomes in recipients of transplants for myeloid malignancies.